CN102731516B - 一类具有抗肿瘤活性的喜树碱衍生物 - Google Patents

一类具有抗肿瘤活性的喜树碱衍生物 Download PDF

Info

Publication number
CN102731516B
CN102731516B CN201110086102.6A CN201110086102A CN102731516B CN 102731516 B CN102731516 B CN 102731516B CN 201110086102 A CN201110086102 A CN 201110086102A CN 102731516 B CN102731516 B CN 102731516B
Authority
CN
China
Prior art keywords
oxygen base
compound
camptothecine
tertiary butyl
ethyl oxime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201110086102.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102731516A (zh
Inventor
雷晓光
张秀国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fu'an Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co. Ltd.
Original Assignee
NINGBO TEAM PHARM Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201110086102.6A priority Critical patent/CN102731516B/zh
Application filed by NINGBO TEAM PHARM Co Ltd filed Critical NINGBO TEAM PHARM Co Ltd
Priority to KR1020137020846A priority patent/KR101575079B1/ko
Priority to RU2013149416/04A priority patent/RU2561118C2/ru
Priority to PCT/CN2012/073578 priority patent/WO2012136144A1/zh
Priority to JP2014502977A priority patent/JP5755796B2/ja
Priority to EP12768102.1A priority patent/EP2695884B1/en
Priority to US14/006,102 priority patent/US9006439B2/en
Publication of CN102731516A publication Critical patent/CN102731516A/zh
Application granted granted Critical
Publication of CN102731516B publication Critical patent/CN102731516B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201110086102.6A 2011-04-07 2011-04-07 一类具有抗肿瘤活性的喜树碱衍生物 Active CN102731516B (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN201110086102.6A CN102731516B (zh) 2011-04-07 2011-04-07 一类具有抗肿瘤活性的喜树碱衍生物
RU2013149416/04A RU2561118C2 (ru) 2011-04-07 2012-04-06 Производные камптотецина, обладающие противоопухолевой активностью
PCT/CN2012/073578 WO2012136144A1 (zh) 2011-04-07 2012-04-06 一类具有抗肿瘤活性的喜树碱衍生物
JP2014502977A JP5755796B2 (ja) 2011-04-07 2012-04-06 抗腫瘍活性を有するカンプトテシン誘導体
KR1020137020846A KR101575079B1 (ko) 2011-04-07 2012-04-06 일종의 항종양 활성을 갖는 캄프토테신 유도체
EP12768102.1A EP2695884B1 (en) 2011-04-07 2012-04-06 Camptothecin derivatives having anti-tumor activity
US14/006,102 US9006439B2 (en) 2011-04-07 2012-04-06 Camptothecin derivatives having anti-tumor activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110086102.6A CN102731516B (zh) 2011-04-07 2011-04-07 一类具有抗肿瘤活性的喜树碱衍生物

Publications (2)

Publication Number Publication Date
CN102731516A CN102731516A (zh) 2012-10-17
CN102731516B true CN102731516B (zh) 2014-07-02

Family

ID=46968611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110086102.6A Active CN102731516B (zh) 2011-04-07 2011-04-07 一类具有抗肿瘤活性的喜树碱衍生物

Country Status (7)

Country Link
US (1) US9006439B2 (enExample)
EP (1) EP2695884B1 (enExample)
JP (1) JP5755796B2 (enExample)
KR (1) KR101575079B1 (enExample)
CN (1) CN102731516B (enExample)
RU (1) RU2561118C2 (enExample)
WO (1) WO2012136144A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102731516B (zh) 2011-04-07 2014-07-02 宁波天衡药业股份有限公司 一类具有抗肿瘤活性的喜树碱衍生物
CN109400619A (zh) * 2018-12-25 2019-03-01 东北林业大学 10-甲氧基喜树碱水溶性衍生物、制备方法和用途
CN112773812A (zh) * 2020-12-30 2021-05-11 烟台大学 新型喜树碱衍生物制备抗肿瘤药物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1616460A (zh) * 2003-11-10 2005-05-18 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
CN101407516A (zh) * 2008-10-06 2009-04-15 雷晓光 具有抗癌活性的喜树碱衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316352D0 (en) * 1993-08-06 1993-09-22 Erba Carlo Spa Process for the preparation of 9-amino camptothecin
JPH08333370A (ja) * 1995-06-08 1996-12-17 Kyorin Pharmaceut Co Ltd 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
WO2006065780A2 (en) * 2004-12-15 2006-06-22 Novartis Ag Combinations of therapeutic agents for treating cancer
CN101033230B (zh) * 2006-03-10 2010-12-08 中国科学院上海药物研究所 一类喜树碱衍生物及其应用
EP2096113A1 (en) * 2008-02-05 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. 9-substituted camptothecin derivatives as antitumor compounds
CN101407515A (zh) * 2008-11-24 2009-04-15 深圳市盛捷生物技术有限公司 用作cdk抑制剂的喹啉类多环化合物
CN102731516B (zh) 2011-04-07 2014-07-02 宁波天衡药业股份有限公司 一类具有抗肿瘤活性的喜树碱衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1616460A (zh) * 2003-11-10 2005-05-18 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
CN101407516A (zh) * 2008-10-06 2009-04-15 雷晓光 具有抗癌活性的喜树碱衍生物

Also Published As

Publication number Publication date
EP2695884A4 (en) 2014-08-27
US9006439B2 (en) 2015-04-14
CN102731516A (zh) 2012-10-17
EP2695884B1 (en) 2016-06-08
JP5755796B2 (ja) 2015-07-29
JP2014511850A (ja) 2014-05-19
KR101575079B1 (ko) 2015-12-07
RU2013149416A (ru) 2015-05-20
WO2012136144A1 (zh) 2012-10-11
RU2561118C2 (ru) 2015-08-20
EP2695884A1 (en) 2014-02-12
US20140011833A1 (en) 2014-01-09
KR20130124532A (ko) 2013-11-14

Similar Documents

Publication Publication Date Title
ZA200406927B (en) Crystalline polymorphic form of irinotecan hydrochloride
CN110483608A (zh) 沙蟾毒精衍生物及其制备方法、包含该衍生物的组合物、及其用途
CN102731517A (zh) 喜树碱衍生物、其制备方法及其在制备治疗肿瘤药物中的应用
CN113845551B (zh) 一种具有光动力抗三阴乳腺癌活性的Pt(Ⅱ)配合物及其制备方法和应用
CN102731516B (zh) 一类具有抗肿瘤活性的喜树碱衍生物
RU2411244C2 (ru) Производные камптотецина и их применение
CN101012227A (zh) 具有抗肿瘤作用的13－正－辛基小檗碱新衍生物
CN108017656A (zh) 喜树碱衍生物及其在制备抗肿瘤药物中的应用
CN107141284B (zh) 黄连碱类衍生物、其制备方法、药物组合物及抗肿瘤用途
CN102336904B (zh) 一种喜树碱及其衍生物的多价peg修饰物及其用途
CN110078770B (zh) 一种具有喹啉酮四价铂结构的化合物、制备方法及其在制备抗肿瘤药物中的应用
CN107488187B (zh) 苦豆子碱二聚体a～d在制备抗炎或抗肿瘤药物制剂中的应用
EP1689400A2 (en) Novel compound, corresponding compositions, preparation and/or treatment methods
CN101463029B (zh) 紫杉烷衍生物及其制法和用途
EP2197279B1 (en) C10-substituted camptothecin analogs
CN112279863A (zh) Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用
CN101402640B (zh) 双酯化喜树碱衍生物及其制备方法和应用
CN102786458B (zh) 吡咯甲酰胺衍生物、其制备方法和用途
CN101941967A (zh) 13a-（S）去氧娃儿藤宁的盐、其制法和药物组合物与用途
CN106188094B (zh) 异噁唑环类衍生物及其制备方法和应用
CN102838652B (zh) 一种具有抗恶性肿瘤作用的齐墩果酸衍生物及其制备方法和用途
CN102086207A (zh) 一类具有抗肿瘤活性的喜树碱衍生物
Yu et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs
CN101407516A (zh) 具有抗癌活性的喜树碱衍生物
CN119176815A (zh) 一类喜树碱-20-位酯衍生物及其制法和其药物组合物与用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
ASS Succession or assignment of patent right

Free format text: FORMER OWNER: ZHANG XIUGUO

Effective date: 20120927

Owner name: NINGBO TEAMPHARM CO., LTD.

Free format text: FORMER OWNER: LEI XIAOGUANG

Effective date: 20120927

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 100101 CHAOYANG, BEIJING TO: 315201 NINGBO, ZHEJIANG PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20120927

Address after: Three Lu Zhuang City Zhenhai District 315201 Zhejiang city of Ningbo province No. 6 Ningbo Tianheng Pharmaceutical Co. Ltd.

Applicant after: Ningbo Teampharm Co., Ltd.

Address before: 100101, Beijing, Chaoyang District Hui Yi Bei Yi Park, 26 floor, 2001

Applicant before: Lei Xiaoguang

Applicant before: Zhang Xiuguo

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent for invention or patent application
CB02 Change of applicant information

Address after: Three Lu Zhuang City Zhenhai District 315201 Zhejiang city of Ningbo province No. 6 Ningbo Tianheng pharmaceutical Limited by Share Ltd

Applicant after: NINGBO TEAM PHARM CO., LTD.

Address before: Three Lu Zhuang City Zhenhai District 315201 Zhejiang city of Ningbo province No. 6 Ningbo Tianheng Pharmaceutical Co. Ltd.

Applicant before: Ningbo Teampharm Co., Ltd.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NINGBO TEAMPHARM CO., LTD. TO: NINGBO TEAM PHARMACEUTICAL CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: FU AN PHARMACEUTICAL GROUP NINGBO TEAM PHARM CO.,

Free format text: FORMER NAME: NINGBO TEAM PHARMACEUTICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Three Lu Zhuang City Zhenhai District 315201 Zhejiang city of Ningbo province No. 6 Ningbo Tianheng pharmaceutical Limited by Share Ltd

Patentee after: Fu'an Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co. Ltd.

Address before: Three Lu Zhuang City Zhenhai District 315201 Zhejiang city of Ningbo province No. 6 Ningbo Tianheng pharmaceutical Limited by Share Ltd

Patentee before: NINGBO TEAM PHARM CO., LTD.